In November 2022, WHO launched a strategy to address antimalarial drug resistance in Africa, emphasizing the need for stronger surveillance. While regional monitoring networks have been active in other regions, most in Africa have not convened since 2017–2018. To renew collaboration, WHO organized a meeting bringing together countries from the African and Eastern Mediterranean regions. Participants shared recent data on antimalarial efficacy and resistance. While artemisinin-based combination therapies remain highly effective, some sites in Uganda and the United Republic of Tanzania reported lower-than-expected efficacy of artemether–lumefantrine. Delayed parasite clearance linked to Plasmodium falciparum Kelch-13 mutations was noted in Eritrea, Rwanda, Uganda and the United Republic of Tanzania. Discussions highlighted challenges in therapeutic efficacy studies, molecular marker surveillance and the need for improved genotyping to distinguish relapses from new infections.